These TKIs include Anaplastic Lymphoma Kinase (ALK) inhibitors, such as crizotinib and alectinib, for ALK fusion‐positive sarcomas and TRK inhibitors, such as larotrectinib and entrectinib, for NTRK fusion‐positive sarcomas [1]. Here, NTRK1 is linked to sarcoma.